Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Buyse

Showing results (31-40 of 227) with videos related to

Pageof 23
Sort By:
Drugs|March 25, 2017
Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid TumorsStefan Michiels, Everardo D Saad, Marc Buyse
Perspectives in Clinical Research|February 7, 2015
Common pitfalls in statistical analysis: "No evidence of effect" versus "evidence of no effect"Priya Ranganathan, C S Pramesh, Marc Buyse
Perspectives in Clinical Research|May 4, 2016
Common pitfalls in statistical analysis: The perils of multiple testingPriya Ranganathan, C S Pramesh, Marc Buyse
Perspectives in Clinical Research|April 17, 2015
Common pitfalls in statistical analysis: "P" values, statistical significance and confidence intervalsPriya Ranganathan, C S Pramesh, Marc Buyse
The New England Journal of Medicine|April 10, 2024
Acoramidis in Transthyretin Amyloid CardiomyopathyJohan Verbeeck, Mickaël De Backer, Marc Buyse
European Heart Journal. Acute Cardiovascular Care|January 11, 2025
From non-inferiority to superiority: the shift towards patient-centric outcomesJohan Verbeeck, Mickaël De Backer, Marc Buyse
The New England Journal of Medicine|November 1, 2016
Adaptive Randomization of Neratinib in Early Breast CancerMarc Buyse, Everardo D Saad, Tomasz Burzykowski
Perspectives in Clinical Research|August 1, 2015
Common pitfalls in statistical analysis: Clinical versus statistical significancePriya Ranganathan, C S Pramesh, Marc Buyse
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2016
Neoadjuvant as Future for Drug Development in Breast Cancer--LetterMarc Buyse, Tomasz Burzykowski, Everardo D Saad
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2003
Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancerAngelo Di Leo, Harry Bleiberg, Marc Buyse
Pageof 23

Showing results (31-40 of 227) with videos related to

Sort By:
Pageof 23
Drugs|March 25, 2017
Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid TumorsStefan Michiels, Everardo D Saad, Marc Buyse
Perspectives in Clinical Research|February 7, 2015
Common pitfalls in statistical analysis: "No evidence of effect" versus "evidence of no effect"Priya Ranganathan, C S Pramesh, Marc Buyse
Perspectives in Clinical Research|May 4, 2016
Common pitfalls in statistical analysis: The perils of multiple testingPriya Ranganathan, C S Pramesh, Marc Buyse
Perspectives in Clinical Research|April 17, 2015
Common pitfalls in statistical analysis: "P" values, statistical significance and confidence intervalsPriya Ranganathan, C S Pramesh, Marc Buyse
The New England Journal of Medicine|April 10, 2024
Acoramidis in Transthyretin Amyloid CardiomyopathyJohan Verbeeck, Mickaël De Backer, Marc Buyse
European Heart Journal. Acute Cardiovascular Care|January 11, 2025
From non-inferiority to superiority: the shift towards patient-centric outcomesJohan Verbeeck, Mickaël De Backer, Marc Buyse
The New England Journal of Medicine|November 1, 2016
Adaptive Randomization of Neratinib in Early Breast CancerMarc Buyse, Everardo D Saad, Tomasz Burzykowski
Perspectives in Clinical Research|August 1, 2015
Common pitfalls in statistical analysis: Clinical versus statistical significancePriya Ranganathan, C S Pramesh, Marc Buyse
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2016
Neoadjuvant as Future for Drug Development in Breast Cancer--LetterMarc Buyse, Tomasz Burzykowski, Everardo D Saad
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2003
Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancerAngelo Di Leo, Harry Bleiberg, Marc Buyse
Pageof 23